Physician profile
Peter Wrobel
NPI 1396761987
$3,327.85
in general payments reported to CMS, 2019-2025
24 companies · $475 in 2025
The $475 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $381 · 2020: $225 · 2021: $714 · 2022: $412 · 2023: $635 · 2024: $485 · 2025: $475.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,595.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,595.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $902.60 | 2020-2025 | Varithena Administration Pack, General - Pain Management |
| Medtronic, INC. | $810.02 | 2021-2025 | Venaseal, Closurefast |
| Bard Peripheral Vascular, INC. | $460.83 | 2021-2022 | |
| Novo Nordisk INC | $180.09 | 2019-2025 | Ozempic, Rybelsus |
| Astellas Pharma US INC | $173.39 | 2019-2024 | Veozah |
| Allergan, INC. | $170.36 | 2019-2022 | |
| Abbvie INC. | $146.57 | 2021-2024 | Botox |
| Medtronic Vascular, INC. | $75.06 | 2019 | |
| Glaxosmithkline, LLC. | $65.75 | 2019-2022 | |
| Pfizer INC. | $44.50 | 2019-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $36.61 | 2019-2021 | |
| Organogenesis INC. | $36.11 | 2020-2022 | |
| Novartis Pharmaceuticals Corporation | $35.95 | 2019-2022 | |
| Amgen INC. | $31.30 | 2019-2022 | |
| Eisai INC. | $23.76 | 2021 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $21.78 | 2019 | |
| Corcept Therapeutics | $15.75 | 2024 | Korlym |
| Astrazeneca Pharmaceuticals LP | $15.54 | 2019 | |
| Genentech USA, INC. | $14.57 | 2019 | |
| Abbott Laboratories | $14.44 | 2021 | |
| Almatica Pharma LLC | $14.23 | 2021 | |
| Aytu Biopharma, INC. | $13.55 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $13.02 | 2020 | |
| Hikma Pharmaceuticals USA | $12.07 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Wrobel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.